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CC BY-NC-ND license (http://creativeAbstract The safety of patients with epilepsy consuming sweetening agents, which is
becoming increasingly prevalent for various reasons, is a topic that should be emphasized
as sensitively as it is for other diseases. Patients with epilepsy consume sweetening agents
for different reasons such being diabetic or overweight. They can occasionally be exposed
to sweetening agents unrestrainedly through consuming convenience food, primarily bever-
ages. This study aimed to investigate the effects of rebaudioside A (Reb-A), which is a steviol
glycoside produced from the herb Stevia rebaudiana (Bertoni), on epileptic seizures and con-
vulsions induced by pentylenetetrazole (PTZ). Forty-eight male rats were used. Twenty-four
rats were administered 35 mg/kg PTZ to trigger epileptiform activity; the remaining 24 rats
were administered 70 mg/kg PTZ to trigger the convulsion model. The epileptiform activity
was evaluated by spike percentage, whereas convulsion was evaluated by Racine’s Convulsion
Scale and the onset time of the first myoclonic jerk. Statistical analysis revealed a statistically
significant decrease in the Racine’s Convulsion Scale score and increase in the latency of first
myoclonic jerk in a dose-dependent manner for the rat groups in which PTZ epilepsy had been
induced and Reb-A had been administered. For the groups that were administered Reb-A, the
spike decrease was apparent in a dose-dependent manner, based on the spike percentageeclare no conflicts of interest.
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Positive effects of Reb-A on PTZ-induced seizures 447calculation. These results indicated that Reb-A has positive effects on PTZ-induced convul-
sions.
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Epilepsy is a disease that affects more than 50 million
people worldwide [1]. Epilepsy frequently coexists with
obesity, which is becoming a prevalent and serious public
health problem [2]. The unrestrained increase in obesity
and type-2 diabetes that began in the second half of the
20th century continues rapidly. An estimated 500 million
obese and 1.5 billion overweight people exist worldwide
[3]. More than two-thirds of the United States population is
obese, and an estimated 86.3% of the adult population will
be affected by the year 2030 [4]. It is estimated that dia-
betes mellitus affects approximately 382 million people
globally. This number is expected to increase to approxi-
mately 592 million people by 2035 [5].
Obesity is sometimes comorbid with epilepsy, but some
occurrences of obesity can also be explained by antiepileptic
treatment [2]. The weight gain effect is common for certain
antiepileptic agents frequently used among epilepsy pa-
tients such as valproic acid, carbamazepine, gabapentine,
and vigabatrine [6]. The comorbidity of two ubiquitous dis-
eases such as diabetes and epilepsy is also frequent.
Epilepsy patients consume sweetening agents for
different reasons such as having diabetes or being over-
weight. They can occasionally be exposed unrestrainedly to
such sweetening agents through consuming convenience
food, primarily beverages. Rebaudioside A (Reb-A) is a
steviol glycoside derived from the herb Stevia rebaudiana
(Bertoni) [7]. Can the safety of these sweetening agents
used by patients with epilepsy be determined by means of
epileptic seizures? This study aimed to investigate the ef-
fects of Reb-A, which has not previously been evaluated
from this point of view.Materials and methods
Animals and laboratory
All experiments and protocols described in the present
study were performed in accordance with the Guide for the
Care and Use of Laboratory Animals, as adopted by United
States National Institutes of Health, and approved by the
Medical Faculty Experimental Ethics Committee of Gaz-
iosmanpasa University (Tokat, Turkey). This study used 48
male SpragueeDawley ratsd24 rats for electroencephalo-
graphic (EEG) recording and 24 rats for behavioral stud-
iesdeach weighing 200e250 g. The rats were maintained
under a 12 hour light/dark cycle (light from 07:00 to 19:00)
in a quiet room with 22Ce24C ambient temperature. They
were provided free access to standard rat nutrients and
purified drinking water ad libitum.Drugs
Pentylenetetrazol (PTZ; SigmaeAldrich, Interlab Inc.,
Istanbul, Turkey) and Reb-A (Candarel Stevia; Aris Inc.,
Istanbul, Turkey) were dissolved in 0.9% saline. Drug solu-
tions were prepared fresh each morning.
Experimental procedures
Forty-eight rats were randomly divided into two groups:
Group A for EEG recordings and Group B for behavioral
assessment. For the EEG recordings, the rats were deeply
anesthetized with 80 mg/kg ketamine HCL (Ketalar; Pfizer
Pharmaceuticals, Istanbul, Turkey) and 4 mg/kg xylazine
(Rompun, Bayer AG., Istanbul, Turkey) mixture adminis-
tered intraperitoneally (i.p.). After inducing anesthesia, a
small hole in the skull was opened stereotaxically with a
drill. The electrodes (polyamide-coated stainless steel
wires, 0.1-mm diameter, and electrical resistance <1U/
10 mm) were implanted on the dura of the left frontal
cortex (2.0 mm lateral to the midline and 1.5 mm anterior
to the bregma). The reference electrode was implanted
over the cerebellum (1.5 mm posterior to the lambda on
the midline). After the implantation, the electrodes were
fixed by dental acrylic. Twelve days after electrode fixa-
tion, 24 rats were divided randomly into four groups (Group
A1eGroup A4; 6 rats per group).
Group A1 was the control group; this group received no
medication. Group A2 received 1 mL/kg saline. Group A3
and Group A4 received 100 mg/kg Reb-A and 200 mg/kg
Reb-A, respectively. All administrations were intraperito-
neal. The drugs were administered 30 minutes before the
PTZ injection. All groups, except Group A1, received
35 mg/kg PTZ and an EEG recording. The EEG recordings
were obtained from awake rats in a special container
5 minutes after the PTZ administration.
All EEG recordings and behavioral assessment protocols
were performed as previously described [8]. In summary,
the EEG recordings were taken for 60 minutes, the signals
were amplified 10 thousand times and filtered within a
range of 1e60 Hz. The EEG records were obtained by the
BIOPAC MP150 Data Acquisition System (Biopac System Inc.,
Santa Barbara, CA, USA) and the spike percentage was
evaluated. Two clinical neurophysiologists scored the EEG
data for the spike percentage (which is a reproducible way
of quantifying epileptiform activity to quantify the per-
centage of 1-second bins with at least one spike-wave,
called “spike-wave percentage” [8]). The onset and
cessation of this complex were identified by a higher
amplitude (at least two-fold), compared with the baseline
values. The cumulative duration of spike-wave was detec-
ted within 2-minute intervals.
448 Y. Uyanikgil et al.To perform the behavioral assessment, groups were
formed with the remaining 24 rats (i.e., Group B). These
rats were divided into four groups (Group B1eGroup B4; 6
rats per group). Group B1 was the control group and
received no medication. Group B2 received 1 mL/kg saline.
Group B3 and Group B4 received 100 mg/kg Reb-A and
200 mg/kg Reb-A, respectively. All administrations were
intraperitoneal. The drugs were administered 30 minutes
before the PTZ injection (70 mg/kg, i.p.). Racine’s
Convulsion Scale (RCS) and the onset time of the first
myoclonic jerk (FMJ) were used to evaluate the seizures
(for the injection of PTZ [70 mg/kg] only) as follows: “0”,
no convulsion; “1”, twitching of vibrissae and pinnae; “2”,
motor arrest with more pronounced twitching; 3, motor
arrest with generalized myoclonic jerks (this duration was
recorded for evaluating FMJ onset time); “4”, tonic-clonic
seizure while the animal remained on its feet; “5”, tonic-
clonic seizure with loss of the righting reflex; and “6”, le-
thal seizure. Rats were observed for the onset times of the
FMJ, as previously described [8]. The onset times were
recorded in seconds. Nearly all animals that had tonic
generalized extension died. The observation period for
PTZ-induced seizures was limited to 30 minutes. After this
period, the animals were euthanized.
Statistical analysis
The results are expressed as the mean  the standard error
of the mean. Data analysis was performed by running SPSS
software (Version 15.0; SPSS Inc., Chicago, IL, USA) for
Windows. The ShapiroeWilk test was used to determineFigure 1. Electroencephalographic (EEG) recording. (A) Control
netetrazole and rebaudioside A (100 mg/kg) group; and (D) pentylwhether a population of values had a normal distribution.
The Racine Convulsion scores were evaluated by the Krus-
kaleWallis test. The FMJ onset times were evaluated by
one-way analysis of variance. Post hoc Bonferronni and
ManneWhitney U tests were performed to identify differ-
ences between the experimental groups. The value of
p < 0.05 was accepted as statistically significant.Results
Evaluation of EEG recordings
Group-based samples of EEG recordings of the rats are
shown in Figure 1. The averages of the spike percentages of
each group are given in Table 1. The evaluations showed no
spike indication in the EEG recordings of Group A1. How-
ever, the recordings of Group A2 indicated dense spike
waves (i.e., high spike percentage) that reflect epilepti-
form activity after the 35 mg/kg PTZ injection
(73.2%  3.7%). Because of Reb-A administration, the spike
percentages of Group A3 and Group A4 were decreased at
56.5%  5.9% and 41.8%  4.1%, respectively, compared
with Group A2 (p < 0.05 and p < 0.0001, respectively).
Evaluation of seizures
The RCS scores of the groups and the FMJ onset time aver-
ages are presented in Table 2. The evaluations showed no
convulsive findings for the Group B1 rats; however, high RCS
scores and FMJ values were detected for the Group B2 ratsgroup; (B) pentylenetetrazole and saline group; (C) pentyle-
enetetrazole and rebaudioside A (200 mg/kg) group.
Table 1 Spike percentages by group.
Drug group Spike percentage
Group A1 0%
Group A2 73.2%  3.7%
Group A3 56.5%  5.9% a,*
Group A4 41.8%  4.1% a,**
aCompared with Group A2.
*p < 0.05, ** p < 0.0001.
Group A1 Z the control rats, which received no medication;
Group A2Z the rats received 35 mg/kg pentylenetetrazol (PTZ)
and 1 mL/kg saline; Group A3Z the rats received 35 mg/kg PTZ
and 100 mg/kg rebaudioside A; Group A4 Z the rats received
35 mg/kg PTZ and 200 mg/kg rebaudioside A.
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time, 67.80  4.5 seconds). Because of Reb-A administra-
tion, the spike percentages of Groups B3 and B4 were
decreased at 4.33  0.3 and 3.50  0.2, respectively,
compared with Group B2 (p < 0.05 and p < 0.0001,
respectively). However, the decline was greater in Group B4
than in Group B3 (p < 0.0001). On the other hand, when the
onset times of groups were reviewed, the averages in Group
B3 and Group B4 (85.60  6.70, 115.20  10.30, respec-
tively) were significantly increased, compared with the av-
erages in Group B2 (p < 0.05 and p < 0.001, respectively).
Discussion
Stevia rebaudiana is a very valuable herb that is specific to
South America [7]. It is native to South America, although it
is grown in Paraguay, Brazil, Colombia, Mexico, Uruguay,
Guatemala, Peru, Japan, and South Korea [9,10]. The
indigenous people used S. rebaudiana as a sweetening
agent for centuries in South America [11]. Pure stevioside
extract has been used in food since mid-1970s in Japan
instead of as a defined synthetic sweetening agent. The
leaf extract of this herb has been traditionally used for the
treatment of diabetes [12].Table 2 Comparison of groups by the Racine’s Convulsion
Scale (RCS) score and first myoclonic jerk (FMJ) latency.
Drugs group Convulsion stage
(RCS score)
FMJ onset time (s)
Group B1 0 0
Group B2 5.60  0.2 67.80  4.5
Group B3 4.33  0.3a* 85.60  6.70a*
Group B4 3.50  0.2a**,b** 115.20  10.30 a***
aCompared with Group B2.
bCompared with Group A3.
*p < 0.05.
**p < 0.0001.
***p < 0.001.
Group B1 Z the control rats, which received no medication;
Group B2Z the rats received 70 mg/kg pentylenetetrazol (PTZ)
and 1 mL/kg saline; Group B3Z the rats received 70 mg/kg PTZ
and 100 mg/kg rebaudioside A; Group B4, the rats received
70 mg/kg PTZ and 200 mg/kg rebaudioside A.In contrast to other synthetic sweeteners, S. rebaudiana
(Bertoni) contains a natural sweetening agent that is 250-
to 300-fold sweeter than saccharose. Reasons for its pref-
erence among convenience food manufacturers include
high temperature- and pH-stability [13]. Reb-A and stevio-
side are steviol glycosides derived from the S. rebaudiana
herb [12,14e16].
In the literature, studies on stevioside, which is more
frequently used than Reb-A, have a bias toward steviol
glycosides [16]. Stevioside is a high molecular weight hy-
drophilic diterpenoid glycoside. Digestive enzymes cannot
reduce it, and therefore it cannot be absorbed by the in-
testines. Stevioside is disintegrated with the aid of the in-
testinal bacterial flora. After absorption, it passes to the
liver where it is transformed into steviol glucuronide.
Excretion from the body occurs via bile and urine.
Intestinal microflora metabolize Reb-A into aglykon and
steviol in vitro [17]. The only structural difference between
Reb-A and stevioside is the additional glucose molecule in
Reb-A [18,19]. The basic difference between the pharma-
cokinetic curves of Reb-A and stevioside occurs during the
separation of the glycoside units by intestinal microflora
from the aglykon unit before absorption. Reb-A and ste-
vioside can be rapidly excreted in urine and, more
frequently, in feces after being absorbed and metabolized
in the liver as steviol [17,19].
Limited studies on the mechanism of action of Reb-A
exist in the literature. The quality of current data is
insufficient to explain the potential antiepileptic effect of
Reb-A, although the existing data may provide the anti-
epileptic effect.
Several studies demonstrate the anti-inflammatory ef-
fect of stevioside [20e24]. Steviol glycosides have a strong
anti-inflammatory effect induced by 12-O-tetradecanoyl-
phorbol-13-acetate in mice [23]. S. rebaudiana has the
highest antioxidant capacity among five different types of
herbs (S.eupatoria, S. ovata, S.plummerae, S. salicafolia,
S.serrata) [14].
The seizure-initiating roles of proinflammatory cytokines
are accepted for epileptogenesis. By using the interleukin-
1-beta (IL-1B) gene polymorphism, Kanemoto et al. [25]
compared nonepileptic controls with temporal lobe epi-
lepsy patients with or without cortical sclerosis. They found
a strong coexistence of the IL-1B gene polymorphism and
cortical sclerosis.
Febrile seizures of childhood exist among predisposing
factors of temporal lobe epilepsy. The level of IL-1B level
increases in the central nervous system and plasma in
febrile seizures. Increased IL-1B activates the molecular
pathways over astrocytic IL receptors and nuclear factor
kappa B (NF-kappa B), thereby leading to calcium-
dependent glutamate release [26]. Overexcited glutamate
receptors have initiative effects for seizures and for easing
the effects of spreading [26]. Stevioside suppresses proin-
flammatory cytokines and prevents activation of the NF-
kappa B pathway for many inflammatory diseases and
demonstrates a decreasing effect for inflammation [26].
Reb-A induces insulin secretion from pancreatic beta cells
as a result of intracellular calcium increase by inhibiting
adenosine triphosphate-dependent K channels. This action
leads to cellular depolarization, and subsequently activation
of calcium channels [26]. Stevioside causes vasodilatation by
450 Y. Uyanikgil et al.slowing down theflowof calcium into vascular smoothmuscle
cells [27]. In addition, the effect of Reb-A on electrolytes in
cells of the central nervous system has not been determined.
The effect of Reb-A on intercellular calcium accumulation,
which is responsible forepileptogenesis in thecentral nervous
system, should be investigated [28].
The relationship of free radicals and reactive oxygen
species with many conditions such as cancer, atheroscle-
rosis, degenerative diseases, and resistant epilepsy is well
known. The antioxidant capacity of Stevia has been proved
by various methods in some studies [29,30]. This leads us to
believe that the antioxidant activity of Stevia is also
effective in its antiepileptic mechanism.
A substance with antiepileptic properties must cross the
blood-brain barrier and then bind to the target point or
points to exert an effect. Voltage-gated ion channels,
neurotransmitter receptors, carriers or neurotransmitter
release, and metabolic enzymes ensuring uptake and
metabolism form these target points. In the literature,
there is no study on whether Reb-A crosses the blood-brain
barrier. However, experimental research investigating the
genotoxic effects of stevioside and its metabolites indicate
that stevioside is effective by passing the blood-brain bar-
rier [31,32]. This finding emphasizes the need for advanced
studies on this topic.
The effect of Reb-A on epileptic seizures has not been
previously investigated in the literature. However, studies
exist on a synthetic sweetening agent called aspartame,
which was discovered in 1965. The results of studies of
aspartame show that the sensitivity to seizures may be
increased via an increase of phenylalanine levels [33,34].
Saccharine, one of the most frequently used low-calorie
sweetening agents was discovered in 1878. Studies on
saccharine have mostly been related to the gall bladder,
and research investigating the relationship between
saccharine and epilepsy has not been conducted [11].
As a result of our study of rats with PTZ-induced epi-
lepsy, a decrease in the RCS score and an increase in the
FMJ latency (which is dose-dependently more distinct)
were statistically significant (p < 0.05, p < 0.001,
p < 0.0001). For the groups that were administered Reb-A,
an apparent decrease in spiking occurred in a dose-
dependent manner (p < 0.05 and p < 0.0001). In conclu-
sion, the results we obtained are a reminder that Reb-A
could be safely used in patients with epilepsy.
Our study is just an introduction to this topic, which has
very many uncertainties. Even though PTZ-induced convul-
sions are only an experimental model, not a real epileptic
syndrome, our results showed very important data about
probable anticonvulsant effects of Reb-A. The safety of using
sweetening agents whose consumption by epilepsy patients
is becoming increasingly prevalent for various reasons is a
matter that should be emphasized as sensitively as it is for
other diseases.We believe thatmore studies and data on this
subject are required to reach conclusive results.References
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